AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2289389
Drug: Ampicillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (250 mg, five-day course every six hours)
Trial: 21666156
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of Edmonston-Zagreb measles vaccine (MV) at 6 and 9 months
Trial: 21666156
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of Edmonston-Zagreb measles vaccine (MV) at 6 and 9 months
Trial: 21666156
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: Measles vaccine at 9 months only (for HIV-uninfected children)
Trial: 21666156
Drug: HIV-infected children
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-infected children receiving measles vaccine
Trial: 19626051
Drug: Alemtuzumab monotherapy
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab monotherapy as first-line therapy
Trial: 19626051
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of alemtuzumab
Trial: 19626051
Drug: Alemtuzumab combination
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab combination therapy and consolidation therapy
Trial: 14695461
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (n=89)
Trial: 11236832
Drug: 0.56 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.56 g/kg alcohol with reinforcement (money and verbal approval)
Trial: 11236832
Drug: 0.56 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.56 g/kg alcohol without reinforcement
Trial: 9310521
Drug: Dexamphetamine (DEX)
RxNorm normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine (DEX) 0.15 mg/kg/dose
Trial: 9310521
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.3 mg/kg/dose
Trial: 3805657
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg nightly)
Trial: 3805657
Drug: Sucralfate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (2 g/day)
Trial: 23130649
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg GMZ2 vaccine in pre-school children
Trial: 23130649
Drug: GMZ2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMZ2 vaccine in vaccinated adults
Trial: 17021884
Drug: Dolasetron 1
RxNorm normalized name: dolasetron 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 1 mg/kg body weight during surgery
Trial: 7737712
Drug: Fosinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (10 to 20 mg)
Trial: 2390186
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (OS) containing the concentrated official formula in packets (group A)
Trial: 31109126
Drug: Cascade Ensemble
RxNorm normalized name: CASCADE
DrugBank: Flufenoxuron (DB15006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cascade Ensemble Learning (CELearning) model using XGBoost, Random Forest, ExtraTrees, and Softmax Regression; details on dosage and duration not applicable as this is a computational model.
Trial: 27807887
Drug: Resveratrol 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 480 mg/day for 4 weeks
Trial: 21098476
Drug: 1-dose group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-dose group (500 mg oral dose 2 hours before procedure)
Trial: 21098476
Drug: 2-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose group (500 mg oral dose 2 hours before procedure and an additional dose 8 hours later)
Trial: 21098476
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (1-dose and 2-dose)
Trial: 11935164
Drug: Intracameral injections
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injections of corticosteroids
Trial: 7575694
Drug: Hydroxychloroquine 400
RxNorm normalized name: hydroxychloroquine 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg/day plus Piroxicam 20 mg/day
Trial: 2403063
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms vitamin D daily for 6 weeks
Trial: 7013586
Drug: Levamisole as
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole as an adjunct to routine chemotherapy
Trial: 7013586
Drug: Routine chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine chemotherapy for tuberculosis only (Control)
Trial: 24136368
Drug: Oral glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glycerol
Trial: 24136368
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (glycerol and acetaminophen)
Trial: 23304075
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 10 mL of 0.5% bupivacaine
Trial: 23304075
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 10 mL of 0.5% bupivacaine on one side and 10 mL of normal saline (NSS) placebo on the opposite side
Trial: 23304075
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 10 mL of NSS placebo per side
Trial: 20438534
Drug: Heparin‐induced LDL‐precipitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin‐induced LDL‐precipitation (HELP)
Trial: 18356633
Drug: Conventional amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional amikacin dosing
Trial: 16544143
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m2 and cisplatin 75 mg/m2
Trial: 16544143
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m2, cisplatin 75 mg/m2, and 5‐FU 750 mg/m2/day
Trial: 8911706
Drug: Levocabastine eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine eye drops (0.5 mg/mL)
Trial: 1918421
Drug: Venlafaxine 25
RxNorm normalized name: venlafaxine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 25 mg three times a day
Trial: 1918421
Drug: Venlafaxine 75
RxNorm normalized name: venlafaxine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75 mg three times a day
Trial: 1918421
Drug: Venlafaxine 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 125 mg three times a day
Trial: 7143458
Drug: Therapy focused
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy focused on obtaining orgasm through self‐stimulation
Trial: 21326120
Drug: Auricular acupressure
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupressure therapy for 4 weeks
Trial: 18061058
Drug: Total cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total cholesterol (1 mmol/L lower)
Trial: 9585795
Drug: Ritonavir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (300 mg on day 15, 400 mg on day 16, and 500 mg on days 17 to 24)
Trial: 9585795
Drug: Rifabutin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifabutin (150 mg daily for 24 days) with placebo
Trial: 3127076
Drug: Intravenous NTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous NTG combined with intravenous NAC (5 g 6 hourly)
Trial: 3127076
Drug: Intravenous NTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous NTG alone
Trial: 3127076
Drug: Intravenous NTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous NTG and continuously infused NAC (10 g/day)
Trial: 26121725
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose prior to echocardiography
Trial: 26121725
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral sucrose)
Trial: 16766440
Drug: Hypnotic suggestion
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestion for blindness with increased brightness of the light during suggestion in Study 1
Trial: 22995323
Drug: SB‐656933 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB‐656933 50mg once daily for 28 days
Trial: 22995323
Drug: SB‐656933 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB‐656933 20mg once daily for 28 days
Trial: 19106506
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy with S‐1 and cisplatin (IP group)
Trial: 19106506
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy with S‐1 and cisplatin (IV group)
Trial: 16624457
Drug: Encepur (comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encepur (comparator vaccine, first vaccination)
Trial: 16624457
Drug: Encepur (comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encepur (comparator vaccine, second vaccination)
Trial: 16624457
Drug: Encepur (comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encepur (comparator vaccine, third vaccination)
Trial: 8068472
Drug: Captopril 100
RxNorm normalized name: captopril 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 100 mg/day
Trial: 29452685
Drug: Bilateral subthalamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subthalamic stimulation plus medical therapy
Trial: 27943563
Drug: DCV-TRIO (daclatasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCV-TRIO (daclatasvir 30 mg, asunaprevir 200 mg, beclabuvir 75 mg) twice-daily + sofosbuvir 400 mg once-daily for 4 weeks
Trial: 27943563
Drug: DCV-TRIO (daclatasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCV-TRIO (daclatasvir 30 mg, asunaprevir 200 mg, beclabuvir 75 mg) twice-daily + sofosbuvir 400 mg once-daily for 6 weeks
Trial: 27943563
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with baseline HCV-RNA <2 million IU/mL
Trial: 27943563
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with baseline HCV-RNA ≥2 million IU/mL
Trial: 21174610
Drug: Tailored and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored and dose-dense EC followed by docetaxel (arm A)
Trial: 21174610
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose EC followed by docetaxel (arm B)
Trial: 18339132
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2 g/d
Trial: 18339132
Drug: Sirolimus (SRL)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (SRL) loading dose of 15 mg, 5 mg/d till day 7 and 2 mg/d thereafter
Trial: 16542443
Drug: Solution-focused follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused follow-up (n = 53)
Trial: 27017450
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (n = 50)
Trial: 12685885
Drug: Inhaled zanamivir
RxNorm normalized name: zanamivir Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled zanamivir 10 mg via Diskhaler twice daily for 5 days
Trial: 11105734
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg daily, titrated to a maximum of 200 mg daily)
Trial: 9365042
Drug: Serum anti‐p53
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum anti‐p53 antibody positivity
Trial: 9365042
Drug: p53 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p53 antibody
Trial: 9365042
Drug: Bilirubin and
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilirubin and p53 antibody
Trial: 1556197
Drug: Sensory Integration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensory Integration Therapy (SI)
Trial: 30955980
Drug: 1 booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 booster dose of 45 mcg of IIV1 A/H7N9 hemagglutinin
Trial: 19892414
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care intervention (professional oral care from a dentist three times a week for 1 year)
Trial: 19892414
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral care intervention)
Trial: 12391509
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (220 micro g/puff) at 2 puffs twice daily for 3 months
Trial: 9927363
Drug: CT (Conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (Conservative Treatment)
Trial: 21153417
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg/day 3 hours before racing
Trial: 11777296
Drug: Selective α1-blockers
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Selective α1-blockers
Trial: 11777296
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo or active treatment arms)
Trial: 7951680
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral physostigmine plus clonidine
Trial: 7951680
Drug: Oral physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral physostigmine alone
Trial: 3295935
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of clonidine
Trial: 29249618
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery combined with relaxation therapy and other complementary therapies (e.g., hand and foot 'M' technique, education on pain management, relaxation exercises, respiration exercises, meditation, soothing music, nature sounds)
Trial: 29100709
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (Cohort 2)
Trial: 25660434
Drug: Duloxetine 60-120
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60-120 mg/d
Trial: 12959269
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg every 12 h
Trial: 12959269
Drug: Nicardipine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 50 mg every 12 h
Trial: 12959269
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metoprolol and nicardipine
Trial: 2888152
Drug: Quazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quazepam (15 or 30 mg)
Trial: 2888152
Drug: Triazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.5 or 1.0 mg)
Trial: 17322150
Drug: golimumab (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab (0.1, 0.3, 1, 3, 6, or 10 mg/kg)
Trial: 15564757
Drug: Topical brinzolamide
RxNorm normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical brinzolamide
Trial: 7603218
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin supplement (1 mg vitamin B12, 1.1 mg folate, 5 mg vitamin B6)
Trial: 7603218
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin supplement
Trial: 2665884
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (50 mg i.m. every 3 weeks)
Trial: 391427
Drug: Fixed alternate
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed alternate treatment program involving Adriamycin and L‐PAM and Cytoxan, 5‐Fluorouracil, and Prednisone
Trial: 391427
Drug: Fixed alternate
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed alternate treatment program
Trial: 391427
Drug: Induction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction treatment programs (Adriamycin and L‐PAM versus Cytoxan, 5‐Fluorouracil, and Prednisone)
Trial: 391427
Drug: Fixed alternating
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed alternating treatment group
Trial: 31994720
Drug: Intravenous ET-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ET-1 infusion (8 ng/kg/min for 20 minutes)
Trial: 26082203
Drug: Dexamethasone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1.25 mg
Trial: 19301940
Drug: Klarithran MR
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Klarithran MR (generic formulation of clarithromycin)
Trial: 19301940
Drug: Klacid XL
RxNorm normalized name: XL-888
DrugBank: XL-888 (DB12981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Klacid XL (originator formulation of clarithromycin)
Trial: 17709915
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg daily for 3 months
Trial: 17709915
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg daily for 3 months
Trial: 9663813
Drug: Dihydrocodeine 60
RxNorm normalized name: dihydrocodeine bitartrate 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine 60 mg with quinidine 50 mg
Trial: 2595270
Drug: Citrate (46
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate (46 mmol/l) in effervescent glucose-electrolyte solution
Trial: 2595270
Drug: Betaine (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine (36 mmol/l) in effervescent glucose-electrolyte solution
Trial: 3003317
Drug: Bicarbonate-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate-containing oral rehydration solution
Trial: 29241890
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (chemotherapy for all)
Trial: 22105586
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg)
Trial: 11453509
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB) nasal spray, 42 micrograms/spray, administered intranasally twice daily for two weeks.
Trial: 11453509
Drug: Saline nasal
RxNorm normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline nasal spray (placebo), administered intranasally twice daily for two weeks.
Trial: 1552095
Drug: Quinidine (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (1,500 mg/day for days 1-3, then 1,500 mg + verapamil 240 mg/day for days 4-6)
Trial: 7846938
Drug: Quinidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine and verapamil (1,500 mg + 240 mg/day)
Trial: 1552095
Drug: Amiodarone (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (1,200 mg/day intravenously for days 1-3, then 800 mg/day orally for days 4-14)
Trial: 7846938
Drug: Quinidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine and verapamil (480 mg/day + 240 mg/day)
Trial: 3276824
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (CAFVP followed by surgery or RT)
Trial: 31564697
Drug: Serum MMP‐9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum MMP‐9 levels in patients with PSD (658.8 ng/mL)